

## Coding for BAVENCIO® (avelumab) Injection 20 mg/mL

BAVENCIO® (avelumab) is indicated for the treatment of:

- Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)
- Patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Please refer to the tables below for examples of codes that may be appropriate for BAVENCIO for the treatment of its FDA-approved indications.

### Healthcare Common Procedure Coding System (HCPCS)

HCPCS coding requirements will vary by payer, setting of care, and date of service. Please verify patient-specific insurance benefits to confirm specific coding and billing guidelines for BAVENCIO.

HCPCS Code	HCPCS Description	Note
J9023	Injection, avelumab, 10 mg	For all payers and settings of care for which HCPCS codes are reported

- J9023 is effective for claims with dates of service on or after January 1, 2018<sup>1</sup>
- 1 unit of J9023 equals 10 mg of avelumab. As a result, 20 units of J9023 equals one 200 mg single-use vial of BAVENCIO, and 80 units equals 800 mg, the recommended dosage for BAVENCIO. Actual units reported will vary by dosage required for each individual patient, and any specific billing instructions required by the local payer
- Beginning January 1, 2017, Medicare claims require the use of the JW modifier (drug amount discarded/not administered to any patient) when applicable.<sup>2</sup> Other payers may have similar requirements

### National Drug Codes (NDCs)

BAVENCIO NDC (11-digit)	Description
44087-3535-01	BAVENCIO is supplied in a single-dose vial of 200 mg/10 mL (20 mg/mL) individually packed
AXITINIB NDCs (11-digit)	Description
00069-0145-01	1 mg tablets in bottles of 180
00069-0151-11	5 mg tablets in bottles of 60

### Current Procedural Terminology (CPT®) Codes for Drug Administration Service

The recommended dose of BAVENCIO is 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. In the event of grade 1 or 2 infusion-related reaction, the Dosage Modification section of the Prescribing Information directs providers to interrupt or slow the infusion rate. Please refer to the full BAVENCIO Prescribing Information for complete Dosage and Administration guidelines. When used in combination with axitinib for advanced RCC, also review the full Prescribing Information for axitinib prior to initiation.

CPT Code	CPT Code Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)

CPT Copyright 2018 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Please see Important Safety Information on pages 3-4. Click for full [Prescribing Information](#) and [Medication Guide](#) for BAVENCIO, or visit [BAVENCIO.com](http://BAVENCIO.com).

## Revenue Codes (for Hospital Claims Only)

All hospital claim forms must include a revenue code for each charge line item. The following revenue codes are most relevant for physician-administered drugs.

Revenue Code <sup>3</sup>	Revenue Code Description
0636	Pharmacy – drugs requiring detailed coding
025X	Pharmacy

## Examples of ICD-10-CM<sup>4</sup> Diagnosis Codes for Metastatic Merkel Cell Carcinoma

Code	Code Description	Code	Code Description
C4A.0	Merkel cell carcinoma of lip	C4A.4	Merkel cell carcinoma of scalp and neck
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	C4A.51	Merkel cell carcinoma of anal skin
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	C4A.52	Merkel cell carcinoma of skin of breast
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	C4A.59	Merkel cell carcinoma of other part of trunk
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	C4A.61	Merkel cell carcinoma of right upper limb, including shoulder
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	C4A.62	Merkel cell carcinoma of left upper limb, including shoulder
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	C4A.71	Merkel cell carcinoma of right lower limb, including hip
C4A.30	Merkel cell carcinoma of unspecified part of face	C4A.72	Merkel cell carcinoma of left lower limb, including hip
C4A.31	Merkel cell carcinoma of nose	C4A.8	Merkel cell carcinoma of overlapping sites
C4A.39	Merkel cell carcinoma of other parts of face	C4A.9	Merkel cell carcinoma, unspecified

## Examples of ICD-10-CM<sup>4</sup> Diagnosis Codes for Locally Advanced or Metastatic Urothelial Carcinoma

Code	Code Description	Code	Code Description
C67.0	Malignant neoplasm of trigone of bladder	C65.1	Malignant neoplasm of the right renal pelvis
C67.1	Malignant neoplasm of dome of bladder	C65.2	Malignant neoplasm of the left renal pelvis
C67.2	Malignant neoplasm of lateral wall of bladder	C65.9	Malignant neoplasm of the unspecified renal pelvis
C67.3	Malignant neoplasm of anterior wall of bladder	C66.1	Malignant neoplasm of the right ureter
C67.4	Malignant neoplasm of posterior wall of bladder	C66.2	Malignant neoplasm of the left ureter
C67.5	Malignant neoplasm of bladder neck	C66.9	Malignant neoplasm of the unspecified ureter
C67.6	Malignant neoplasm of ureteric orifice	C68.0	Malignant neoplasm of urethra
C67.7	Malignant neoplasm of urachus	C61	Malignant neoplasm of prostate (reporting “urothelial carcinoma of the prostate”)
C67.8	Malignant neoplasm of overlapping sites of bladder	Z85.51	Personal history of malignant neoplasm of bladder
C67.9	Malignant neoplasm of bladder, unspecified	D09.0	Carcinoma in situ of bladder

Please see Important Safety Information on pages 3-4. Click for full [Prescribing Information](#) and [Medication Guide](#) for BAVENCIO, or visit [BAVENCIO.com](#).

Examples of ICD-10-CM<sup>4</sup> Diagnosis Codes for Advanced Renal Cell Carcinoma

Code	Code Description	Code	Code Description
C64.1	Malignant neoplasm of right kidney, except renal pelvis	C65.1	Malignant neoplasm of the right renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis	C65.2	Malignant neoplasm of the left renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	C65.9	Malignant neoplasm of the unspecified renal pelvis
		Z85.528	Personal history of other malignant neoplasm of kidney

Please contact **CoverOne® at 1-844-8COVER1 (844-826-8371)** for support with payer-specific BAVENCIO® (avelumab) questions or assistance verifying insurance benefits for a specific patient.

Pfizer Oncology Together™ provides personalized support and financial assistance resources to help patients access their prescribed axitinib. To learn more, call **1-877-744-5675** (Monday–Friday 8 AM–8 PM ET) or visit **PfizerOncologyTogether.com**.

*This document is for informational purposes only. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for products and services rendered. EMD Serono, Inc. and Pfizer Inc do not guarantee coverage and/or reimbursement for BAVENCIO. Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Patients and healthcare professionals should always verify coverage, coding, and reimbursement guidelines on a payer- and patient-specific basis.*

<sup>1</sup>Centers for Medicare and Medicaid Services (CMS), 2018 Alpha-Numeric HCPCS File, November 2017; <sup>2</sup>Source: Centers for Medicare and Medicaid Services. Transmittal R3538CP: JW Modifier: Drug amount discarded/not administered to any patient. <sup>3</sup>Revenue code 0636 is required by Medicare. For payers other than Medicare, the revenue code may vary; although some private payers and Medicaid plans accept revenue code 0636, others may require a different revenue code, such as 0250. <sup>4</sup>International Classification of Diseases, 10th Revision, Clinical Modification.

## IMPORTANT SAFETY INFORMATION FOR BAVENCIO® (avelumab) Injection 20 mg/mL

BAVENCIO® (avelumab) can cause **immune-mediated pneumonitis**, including fatal cases. Monitor patients for signs and symptoms of pneumonitis, and evaluate suspected cases with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis occurred in 1.2% of patients, including one (0.1%) patient with Grade 5, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.

BAVENCIO can cause **hepatotoxicity and immune-mediated hepatitis**, including fatal cases. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO for moderate (Grade 2) immune-mediated hepatitis until resolution and permanently discontinue for severe (Grade 3) or life-threatening (Grade 4) immune-mediated hepatitis. Immune-mediated hepatitis occurred with BAVENCIO as a single agent in 0.9% of patients, including two (0.1%) patients with Grade 5, and 11 (0.6%) with Grade 3.

*BAVENCIO in combination with axitinib* can cause **hepatotoxicity** with higher than expected frequencies of Grade 3 and 4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation. Consider more frequent monitoring of liver enzymes as compared to when the drugs are used as monotherapy. Withhold BAVENCIO and axitinib for moderate (Grade 2) hepatotoxicity and permanently discontinue the combination for severe or life-threatening (Grade 3 or 4) hepatotoxicity. Administer corticosteroids as needed. In patients treated with BAVENCIO in combination with axitinib, Grades 3 and 4 increased ALT and AST occurred in 9% and 7% of patients, respectively, and immune-mediated hepatitis occurred in 7% of patients, including 4.9% with Grade 3 or 4.

BAVENCIO can cause **immune-mediated colitis**. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO until resolution for moderate or severe (Grade 2 or 3) colitis until resolution. Permanently discontinue for life-threatening (Grade 4) or recurrent (Grade 3) colitis upon reinitiation of BAVENCIO. Immune-mediated colitis occurred in 1.5% of patients, including seven (0.4%) with Grade 3.

BAVENCIO can cause **immune-mediated endocrinopathies**, including adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus.

Monitor patients for signs and symptoms of **adrenal insufficiency** during and after treatment, and administer corticosteroids as appropriate. Withhold BAVENCIO for severe (Grade 3) or life threatening (Grade 4) adrenal insufficiency. Adrenal insufficiency was reported in 0.5% of patients, including one (0.1%) with Grade 3.

**Thyroid disorders** can occur at any time during treatment. Monitor patients for changes in thyroid function at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation. Manage hypothyroidism with hormone replacement therapy and hyperthyroidism with medical management. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) thyroid disorders. Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroiditis, were reported in 6% of patients, including three (0.2%) with Grade 3.

**Type 1 diabetes mellitus** including diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Withhold BAVENCIO and administer antihyperglycemics or insulin in patients with severe or life-threatening (Grade ≥ 3) hyperglycemia, and resume treatment when metabolic control is achieved. Type 1 diabetes mellitus without an alternative etiology occurred in 0.1% of patients, including two cases of Grade 3 hyperglycemia.

**IMPORTANT SAFETY INFORMATION FOR BAVENCIO® (avelumab) Injection 20 mg/mL (cont'd)**

BAVENCIO can cause **immune-mediated nephritis and renal dysfunction**. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to Grade 1 or lower. Permanently discontinue BAVENCIO for life-threatening (Grade 4) nephritis. Immune-mediated nephritis occurred in 0.1% of patients.

BAVENCIO can result in **other severe and fatal immune-mediated adverse reactions** involving any organ system during treatment or after treatment discontinuation. For suspected immune-mediated adverse reactions, evaluate to confirm or rule out an immune-mediated adverse reaction and to exclude other causes. Depending on the severity of the adverse reaction, withhold or permanently discontinue BAVENCIO, administer high-dose corticosteroids, and initiate hormone replacement therapy, if appropriate. Resume BAVENCIO when the immune-mediated adverse reaction remains at Grade 1 or lower following a corticosteroid taper. Permanently discontinue BAVENCIO for any severe (Grade 3) immune-mediated adverse reaction that recurs and for any life-threatening (Grade 4) immune-mediated adverse reaction. The following clinically significant immune-mediated adverse reactions occurred in less than 1% of 1738 patients treated with BAVENCIO as a single agent or in 489 patients who received *BAVENCIO in combination with axitinib*: myocarditis including fatal cases, pancreatitis including fatal cases, myositis, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, hypopituitarism, uveitis, Guillain-Barré syndrome, and systemic inflammatory response.

BAVENCIO can cause severe or life-threatening **infusion-related reactions**. Premedicate patients with an antihistamine and acetaminophen prior to the first 4 infusions and for subsequent infusions based upon clinical judgment and presence/severity of prior infusion reactions. Monitor patients for signs and symptoms of infusion-related reactions, including pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Infusion-related reactions occurred in 25% of patients, including three (0.2%) patients with Grade 4 and nine (0.5%) with Grade 3.

*BAVENCIO in combination with axitinib* can cause **major adverse cardiovascular events (MACE)** including severe and fatal events. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue BAVENCIO and axitinib for Grade 3-4 cardiovascular events. MACE occurred in 7% of patients with advanced RCC treated with BAVENCIO in combination with axitinib compared to 3.4% treated with sunitinib. These events included death due to cardiac events (1.4%), Grade 3-4 myocardial infarction (2.8%), and Grade 3-4 congestive heart failure (1.8%).

BAVENCIO can cause **fetal harm** when administered to a pregnant woman. Advise patients of the potential risk to a fetus including the risk of fetal death. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least 1 month after the last dose of BAVENCIO. It is not known whether BAVENCIO is excreted in human milk. Advise a lactating woman **not to breastfeed** during treatment and for at least 1 month after the last dose of BAVENCIO due to the potential for serious adverse reactions in breastfed infants.

**The most common adverse reactions** (all grades,  $\geq 20\%$ ) in patients with **metastatic Merkel cell carcinoma (MCC)** were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), infusion-related reaction (22%), rash (22%), decreased appetite (20%), and peripheral edema (20%).

**Selected treatment-emergent laboratory abnormalities** (all grades,  $\geq 20\%$ ) in patients with **metastatic MCC** were lymphopenia (49%), anemia (35%), increased aspartate aminotransferase (34%), thrombocytopenia (27%), and increased alanine aminotransferase (20%).

**The most common adverse reactions** (all grades,  $\geq 20\%$ ) in patients with **locally advanced or metastatic urothelial carcinoma (UC)** were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%), and urinary tract infection (21%).

**Selected laboratory abnormalities** (Grades 3-4,  $\geq 3\%$ ) in patients with **locally advanced or metastatic UC** were hyponatremia (16%), increased gamma-glutamyltransferase (12%), lymphopenia (11%), hyperglycemia (9%), increased alkaline phosphatase (7%), anemia (6%), increased lipase (6%), hyperkalemia (3%), and increased aspartate aminotransferase (3%).

**Fatal adverse reactions** occurred in 1.8% of patients with **advanced renal cell carcinoma (RCC)** receiving BAVENCIO in combination with axitinib. These included sudden cardiac death (1.2%), stroke (0.2%), myocarditis (0.2%), and necrotizing pancreatitis (0.2%).

**The most common adverse reactions** (all grades,  $\geq 20\%$ ) in patients with **advanced RCC** receiving BAVENCIO in combination with axitinib (vs sunitinib) were diarrhea (62% vs 48%), fatigue (53% vs 54%), hypertension (50% vs 36%), musculoskeletal pain (40% vs 33%), nausea (34% vs 39%), mucositis (34% vs 35%), palmar-plantar erythrodysesthesia (33% vs 34%), dysphonia (31% vs 3.2%), decreased appetite (26% vs 29%), hypothyroidism (25% vs 14%), rash (25% vs 16%), hepatotoxicity (24% vs 18%), cough (23% vs 19%), dyspnea (23% vs 16%), abdominal pain (22% vs 19%), and headache (21% vs 16%).

**Selected laboratory abnormalities** (all grades,  $\geq 20\%$ ) worsening from baseline in patients with **advanced RCC** receiving BAVENCIO in combination with axitinib (vs sunitinib) were blood triglycerides increased (71% vs 48%), blood creatinine increased (62% vs 68%), blood cholesterol increased (57% vs 22%), alanine aminotransferase increased (ALT) (50% vs 46%), aspartate aminotransferase increased (AST) (47% vs 57%), blood sodium decreased (38% vs 37%), lipase increased (37% vs 25%), blood potassium increased (35% vs 28%), platelet count decreased (27% vs 80%), blood bilirubin increased (21% vs 23%), and hemoglobin decreased (21% vs 65%).

**Click for full Prescribing Information and Medication Guide for BAVENCIO, or visit [BAVENCIO.com](http://BAVENCIO.com).**